ENTA – Enanta Pharmaceuticals Inc
Float Short %
8.33
Margin Of Safety %
Put/Call OI Ratio
0.1
EPS Next Q Diff
0.1
EPS Last/This Y
0.77
EPS This/Next Y
0.56
Price
13.88
Target Price
17.6
Analyst Recom
1.6
Performance Q
25.36
Relative Volume
0.48
Beta
0.99
Ticker: ENTA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | ENTA | 14.65 | 0.37 | 0.75 | 2997 |
| 2025-12-10 | ENTA | 14.39 | 0.37 | 1.50 | 2999 |
| 2025-12-11 | ENTA | 14.16 | 0.37 | 0.17 | 3000 |
| 2025-12-12 | ENTA | 14.75 | 0.37 | 2.00 | 3004 |
| 2025-12-15 | ENTA | 14.89 | 0.37 | 999.99 | 3007 |
| 2025-12-16 | ENTA | 14.85 | 0.37 | 0.00 | 3010 |
| 2025-12-17 | ENTA | 14.24 | 0.38 | 3.50 | 2990 |
| 2025-12-18 | ENTA | 14.55 | 0.38 | 0.00 | 3004 |
| 2025-12-19 | ENTA | 15.4 | 0.38 | 0.05 | 3033 |
| 2025-12-22 | ENTA | 16.23 | 0.08 | 1.50 | 2324 |
| 2025-12-23 | ENTA | 15.72 | 0.09 | 0.00 | 2331 |
| 2025-12-26 | ENTA | 16.86 | 0.09 | 0.00 | 2387 |
| 2025-12-29 | ENTA | 16.48 | 0.08 | 0.00 | 2429 |
| 2025-12-30 | ENTA | 15.91 | 0.08 | 0.00 | 2428 |
| 2025-12-31 | ENTA | 15.77 | 0.08 | 0.00 | 2428 |
| 2026-01-02 | ENTA | 14.4 | 0.08 | 1.62 | 2426 |
| 2026-01-05 | ENTA | 13.93 | 0.10 | 0.00 | 2511 |
| 2026-01-06 | ENTA | 13.6 | 0.10 | 0.01 | 2541 |
| 2026-01-07 | ENTA | 13.9 | 0.10 | 0.00 | 2613 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | ENTA | 14.64 | 49.1 | - | -2.30 |
| 2025-12-10 | ENTA | 14.64 | 49.1 | - | -2.30 |
| 2025-12-11 | ENTA | 14.14 | 49.1 | - | -2.30 |
| 2025-12-12 | ENTA | 14.75 | 49.1 | - | -2.30 |
| 2025-12-15 | ENTA | 14.87 | 49.1 | - | -2.30 |
| 2025-12-16 | ENTA | 14.87 | 49.1 | - | -2.30 |
| 2025-12-17 | ENTA | 14.24 | 49.1 | - | -2.30 |
| 2025-12-18 | ENTA | 14.53 | 49.1 | - | -3.07 |
| 2025-12-19 | ENTA | 15.43 | 23.1 | - | -3.07 |
| 2025-12-22 | ENTA | 16.21 | 23.1 | - | -3.07 |
| 2025-12-23 | ENTA | 15.77 | 23.1 | - | -3.07 |
| 2025-12-26 | ENTA | 16.85 | 23.1 | - | -3.07 |
| 2025-12-29 | ENTA | 16.44 | 23.1 | - | -3.07 |
| 2025-12-30 | ENTA | 15.91 | 23.1 | - | -3.07 |
| 2025-12-31 | ENTA | 15.77 | 23.1 | - | -3.07 |
| 2026-01-02 | ENTA | 14.41 | 23.1 | - | -3.07 |
| 2026-01-05 | ENTA | 13.93 | 23.1 | - | -3.07 |
| 2026-01-06 | ENTA | 13.56 | 23.1 | - | -3.07 |
| 2026-01-07 | ENTA | 13.88 | 23.1 | - | -3.07 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | ENTA | -0.85 | 15.49 | 10.25 |
| 2025-12-10 | ENTA | -0.85 | 15.49 | 9.07 |
| 2025-12-11 | ENTA | -0.85 | 15.49 | 9.07 |
| 2025-12-12 | ENTA | -0.85 | 15.49 | 9.07 |
| 2025-12-15 | ENTA | -0.85 | 15.46 | 9.05 |
| 2025-12-16 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-17 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-18 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-19 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-22 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-23 | ENTA | -0.88 | 15.46 | 9.05 |
| 2025-12-26 | ENTA | -0.88 | 15.46 | 8.33 |
| 2025-12-29 | ENTA | -0.88 | 15.46 | 8.33 |
| 2025-12-30 | ENTA | -0.88 | 15.46 | 8.33 |
| 2025-12-31 | ENTA | -0.88 | 15.46 | 8.33 |
| 2026-01-02 | ENTA | -0.88 | 15.46 | 8.33 |
| 2026-01-05 | ENTA | -0.88 | 15.46 | 8.33 |
| 2026-01-06 | ENTA | -0.88 | 15.46 | 8.33 |
| 2026-01-07 | ENTA | -0.88 | 15.46 | 8.33 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.87
Avg. EPS Est. Current Quarter
-0.81
Avg. EPS Est. Next Quarter
-0.77
Insider Transactions
-0.88
Institutional Transactions
15.46
Beta
0.99
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
15
Fair Value
Quality Score
19
Growth Score
26
Sentiment Score
10
Actual DrawDown %
86.4
Max Drawdown 5-Year %
-95.6
Target Price
17.6
P/E
Forward P/E
PEG
P/S
6.14
P/B
4.59
P/Free Cash Flow
EPS
-3.84
Average EPS Est. Cur. Y
-3.07
EPS Next Y. (Est.)
-2.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-125.36
Relative Volume
0.48
Return on Equity vs Sector %
-153.6
Return on Equity vs Industry %
-138.5
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
0.08
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 120
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading